MAXHEALTH

Max Healthcare Institute share price & results

Max Healthcare Institute Limited· Healthcare

India's second-largest hospital chain by revenue & EBITDA; 21 facilities, 6,000+ beds nationwide.

₹1,030.9 +2.08%
MCap ₹89.2k Cr Price to earnings (TTM to Sept 2026) 62.79× Return on equity (TTM to Sept 2026) 12.53%

Free account: unlock 50 concall reads/mo, 5 full guidance ledgers, and same-day MAXHEALTH alerts.

Results to: Sept 2026 Latest analysed call: Q2 FY27 Ownership as of: Sept 2026
MAXHEALTH at a glance Plain-English snapshot from filed results & analysed earnings calls

Guidance Track Record

Management guidance vs. actual results

3 of 6 judged targets kept · 28 open · verdicts reflect calls analysed to Q2 FY27.

Max Healthcare Institute Limited management guidance track record on Inve: 34 targets tracked across analysed earnings calls (3 achieved, 3 missed, 28 open).

Watch execution in Growth & Demand (1 achieved · 1 delayed/missed) · Capex & Expansion (1 delayed/missed).

TargetOriginal wordingSaidLatest callVerdict
Growth CGHS rate revision
expecting better rates coming through on CGHS now... hope is that this comes in this quarter.
Q3 FY25
Q2 FY27:No new update; the promise was achieved in Q2 FY26. Management cited the revised CGHS rates as the reason oncology drugs remain discontinued for institutional patients.
Achieved
Growth Additional revenue from CGHS revision
additional INR 200 crore kind of revenue
Q2 FY26
Q2 FY27:Management gave no figure for how much CGHS benefit has been realized against the revised ~INR 140 crore FY27 target. The only CGHS commentary was BLK's May de-empanelment for non-payment, already in effect at the Q1 FY27 'on track' statement, and the oncology drag from the revised rates. The FY27 deadline is two quarters away.
Ghosted
Capex Max Smart (Saket Complex) 400 beds completion
completion within Q1 FY '26
Q3 FY25
Q2 FY27:Missed the Q2 FY27 target to hand over the remaining 50%. About 260 newly added Max Smart beds are operational, up from 200 (50%) in Q1 FY27, and they reached EBITDA breakeven within 3 months. The rest are part of a combined 205-bed balance with Nanavati that 'will be opened post Diwali puja' (Q3 FY27). The original Q1 FY26 target is now about 6 quarters late.
Delayed

Source: Inve Guidance Tracker for Max Healthcare Institute Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Max Healthcare Institute Limited's 34 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 31 more targets are in the full ledger.

Get the Inve app for Android on Google Play Get the Inve app for Android on Google Play Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Latest analysed call · Q2 FY27 · 3 Nov 2026

Q2 FY27: Max Healthcare Institute Limited Q2 FY27

Max Healthcare delivered strong operational performance in Q2 FY27, with gross revenue growing 20% YoY to ₹3,219 crore and operating EBITDA rising 18% YoY to ₹820 crore, sustaining a healthy 26.8% EBITDA margin. Growth was underpinned by stable 77% occupancy despite a 14% YoY increase in operational beds, alongside an 8% increase in IP ARPP to ₹2.31 lakhs. Brownfield ramp-ups at Max Smart Saket, Max Mohali, and Max Nanavati progressed well, with Board approval secured for an additional ₹415 crore brownfield expansion across Noida, Vaishali, and BLK-Max.

What management highlighted

  • Network gross revenue grew 20% YoY to ₹3,219 crore, and Operating EBITDA grew 18% YoY to ₹820 crore
  • International patient revenue jumped 33% YoY to ₹307 crore, contributing 10% of hospital healthcare revenue
  • Free cash flow generation was strong at ₹500 crore for Q2 FY27 (₹897 crore in H1 FY27)

Source: Inve analysis of Max Healthcare Institute Limited’s Q2 FY27 earnings call · to 3 Nov 2026

Compare across 8 analysed calls

Price & Snapshot

₹1,030.9 +2.08% · +₹21

Last close 17 Nov 2026 · NSE · INR · Source: Inve

Performance −6.5% 1Y

₹0.8k₹0.9k₹1.0k₹1.1k₹1.2kNov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 21 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 14 Aug 2026Q2 FY27 — 3 Nov 2026

1Y: ₹1,103.1 on 14 Nov 2025 → ₹1,030.9. High ₹1,181.1 (21 Nov 2025), low ₹815 (23 Oct 2026).

Previous close
₹1,009.9
Market cap
₹89.2k Cr
52-week range
₹815 – ₹1,181.1
One year
−8.09%
Price to earnings (TTM to Sept 2026)
62.79×
Return on equity (TTM to Sept 2026)
12.53%

Reported

Key financial metrics & valuation ratios

Revenue: 2,569 ₹ crore (+20.3% YoY) · Net profit: 414 ₹ crore (−15.7% YoY) · Return on equity: 12.53 % (+2.0 pts). Every row keeps its filed period and basis.

MetricValueChangeBasisPeriodNote
Revenue2,569 ₹ crore+20.3% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin28.0 %+1.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit414 ₹ crore−15.7% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity12.53 %+2.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin1.96 %−5.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)15.17 %−10.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Revenue change against the same period one year earlier.

Source: Quarterly results & TTM/FY financial ratios · to Sept 2026

Customers, suppliers & partners

Customers, suppliers & partner mentions

Named customers, suppliers, and partners mentioned on recent earnings calls. Click any row to read the disclosure.

Counterparties named by Max Healthcare Institute Limited

  • Max Healthcare Institute Limited → acquires or invests in → Yerawada Properties Private Limited (Pune)

    Acquires / invests · Closed / completed · Q2 FY27
  • Max Healthcare Institute Limited → acquires or invests in → Kalinga Hospital Limited (Bhubaneswar)

    Acquires / invests · Closed / completed · Q2 FY27
  • Max Healthcare Institute Limited → acquires or invests in → Yerawada Properties Private Limited (Pune greenfield)

    Acquires / invests · Closed / completed · Q1 FY27
  • Max Healthcare Institute Limited → acquires or invests in → Kalinga Hospital

    Acquires / invests · Closed / completed · INR 153 crores · Q1 FY27
  • Max Healthcare Institute Limited → acquires or invests in → Kalinga Hospital Limited

    Acquires / invests · Closed / completed · Q4 FY26
  • Max Healthcare Institute Limited → acquires or invests in → Crosslay Remedies Ltd. and Jaypee Healthcare Ltd.

    Acquires / invests · Announced · Q2 FY26
  • Max Healthcare Institute Limited → divests to → Hospitals in Chitta and Anoopshahr

    Divests to · Closed / completed · Q2 FY26
  • Max Healthcare Institute Limited → acquires or invests in → Land parcel adjoining Max Vaishali

    Acquires / invests · Announced · Q4 FY25
  • Max Healthcare Institute Limited → acquires or invests in → Crosslay Remedies Limited and Jaypee Healthcare Limited

    Acquires / invests · Announced · INR 200 crores · Q4 FY25
  • Max Healthcare Institute Limited → acquires or invests in → Alps Hospital Limited and Max Hospitals & Allied Services Limited

    Acquires / invests · Closed / completed · Q4 FY25

Similar pressures reported by peers

Tailwind coverage is not available yet.
  • Government scrutiny and potential price caps on trade margins

    53 other companies · Regulatory policy · Q2 FY27

Mentions over time

Q4 2024 – Q3 2026

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Company Reference

Symbol
NSE:MAXHEALTH
Exchange
NSE
Currency
INR

What Max Healthcare Institute Limited does

Sourced to annual report & earnings calls.

Max Healthcare Institute Limited operates a network of quaternary/tertiary-care hospitals and standalone speciality clinics concentrated in Delhi NCR, with additional facilities in Gurugram, Noida, Mumbai, Lucknow, Mohali, Dehradun, Bathinda, Nagpur and Bhubaneshwar. It earns primarily by delivering inpatient hospital care — complex surgeries, transplants and cancer treatment — plus diagnostics and outpatient consultations, across a mix of owned hospitals, asset-light leased/built-to-suit facilities and operations-and-management (O&M) contracts. Beyond hospitals, it runs Max Lab (non-captive pathology/diagnostics) and Max@Home (homecare services) as capital-light adjacent businesses, and operates a network of international Patient Assistance Centres to serve medical-value-travel patients. The group also partners with global academic institutions on medical research, publications and clinical training programs.

Segments

  • Hospitals
  • Max Lab
  • Max@Home
Current bed capacity
6,000+ beds
Hospital network size
21 facilities (hospitals and standalone speciality clinics)
Market position
India's second-largest hospital chain by revenue and EBITDA among listed peers (FY26)
Geographic footprint
Facilities across Delhi NCR plus Gurugram, Noida, Mumbai, Lucknow, Mohali, Dehradun, Bathinda, Nagpur and Bhubaneshwar
Beds in metro cities
4,400+ beds (~73% of total capacity)
International patient network
15 company- and partner-owned Patient Assistance Centres across 14 countries
Founded 2001Headquarters Gurugram, Haryana, India Company website

How the price took the results

Moved an average of ±1.8% across the last 5 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY273 Nov 262,569 414+20.3%₹884.75 → ₹895.5+1.2%
Q1 FY2714 Aug 262,366 323+16.7%₹1,013.3 → ₹1,008.6−0.5%
Q4 FY2622 May 262,143 342+12.2%₹1,091.1 → ₹1,023.25−6.2%
Q3 FY266 Feb 262,068 301+10.7%₹1,040.8 → ₹1,039.85−0.1%
Q2 FY2621 Nov 252,135 491—₹1,168.9 → ₹1,181.1+1.0%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case & results alerts for Max Healthcare Institute Limited

Free account: one Inve Case, 50 concall reads/mo, 5 full ledgers, and results-day alerts.

Write why you follow Max Healthcare Institute Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance, and notifies you when a new call moves your thesis.

Keep reading

Other Healthcare companies

PEER COMPARISON
Median ₹89,161 Cr Mkt Cap
₹0 Cr₹50,000 Cr₹1.0L Cr₹1.5L CrMax Healthcare Institute Limited (MAXHEALTH): ₹89,161 Cr₹89,161 CrMAXHEALTHAurobindo Pharma Limited (AUROPHARMA): ₹1.1L Cr₹1.1L CrAUROPHARMAMankind Pharma Limited (MANKIND): ₹1.0L Cr₹1.0L CrMANKINDMANIPALHOS (MANIPALHOS): ₹92,734 Cr₹92,734 CrMANIPALHOSLupin Limited (LUPIN): ₹92,695 Cr₹92,695 CrLUPINGlenmark Pharmaceuticals Limited (GLENMARK): ₹73,895 Cr₹73,895 CrGLENMARKAster DM Healthcare Limited (ASTERDM): ₹62,957 Cr₹62,957 CrASTERDMAlkem Lab (ALKEM): ₹61,935 Cr₹61,935 CrALKEMBiocon Limited (BIOCON): ₹59,981 Cr₹59,981 CrBIOCON

All Healthcare companies → · Healthcare earnings growth →

Quick Answers

Frequently asked questions on Max Healthcare Institute Limited

Compiled directly from MAXHEALTH's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Max Healthcare Institute Limited (MAXHEALTH) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Max Healthcare Institute Limited reported revenue of ₹2.6k Cr, net profit of ₹414 Cr, an operating margin of 28.0%. Diluted earnings per share stood at ₹4.26.

How is Max Healthcare Institute Limited (MAXHEALTH) valued today, and what growth does the stock price imply?

Max Healthcare Institute Limited (MAXHEALTH) trades at ₹1,030.9, with a market capitalization of ₹89.2k Cr, a trailing P/E multiple of 62.79×, return on equity (ROE) of 14.74%, ROCE of 14.72%. Reverse-DCF analysis shows the current stock price implies 38.7% annual earnings growth over the next 7 years compared with its historical net-profit CAGR of 12.9%.

Did Max Healthcare Institute Limited (MAXHEALTH) management keep or miss its earnings call guidance?

Across 34 management guidance targets tracked from Max Healthcare Institute Limited's earnings calls, 3 were achieved, 3 missed, and 28 remain open (50% delivered among resolved targets). Sampled guidance includes CGHS rate revision: "expecting better rates coming through on CGHS now... hope is that this comes in this quarter." (stated in Q3 FY25, current status: achieved).

Who owns Max Healthcare Institute Limited (MAXHEALTH) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 23.7%, FIIs hold 40.5%, DIIs hold 31.0%, Public shareholders hold 4.8%.

What did Max Healthcare Institute Limited (MAXHEALTH) management cover on its latest concall (Q2 FY27)?

On its Q2 FY27 (Nov 2026) concall, Max Healthcare delivered strong operational performance in Q2 FY27, with gross revenue growing 20% YoY to ₹3,219 crore and operating EBITDA rising 18% YoY to ₹820 crore, sustaining a healthy 26.8% EBITDA margin. Growth was underpinned by stable 77% occupancy despite a 14% YoY increase in operational beds, alongside an 8% increase in IP ARPP to ₹2.31 lakhs. Brownfield ramp-ups at Max Smart Saket, Max Mohali, and Max Nanavati progressed well, with Board approval secured for an additional ₹415 crore brownfield expansion across Noida, Vaishali, and BLK-Max. Read Max Healthcare Institute Limited Q2 FY27 concall summary →